Kamada Ltd. (KMDA) Strengthens Leadership Team With The Addition Of Vice President-Medical Director

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company has strengthened its senior leadership team with the appointment of Eran Schenker, M.D. to the newly created position of Vice President-Medical Director Dr. Schenker will report to David Tsur, co-founder and CEO of Kamada.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.